For adults managing type 2 diabetes or seeking chronic weight management, Eli Lilly’s Mounjaro and Zepbound offer advanced treatment options. Both contain tirzepatide, a dual GIP and GLP-1 receptor agonist. Mounjaro improves blood sugar control, while Zepbound, at a higher dose, targets weight loss. Administered as a weekly injection, these medications help eligible patients achieve significant metabolic health improvements.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends